Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from the sudden departure this past week of Vinayak (Vinay) Prasad, MD, as ...

AbbVie ( ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for its ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Denmark’s status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant’s astronomical ...

Trade deficit data, Federal Reserve officials' remarks, earnings from Pfizer, Disney, Uber, and additional companies.

The pharmaceutical industry continues to evolve rapidly, driven by innovation, global health challenges, and technological ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Hims & Hers Health ($HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS ...